An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 May 2019
Price : $35 *
At a glance
- Drugs Arbaclofen (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Osmotica Pharmaceutical
- 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.